Antoine Pouppez

Overview

Antoine Pouppez is co-founder and chief executive of neuroClues, a company he co-founded in January 2020. He is based in Brussels and states expertise in medical devices, project management and team leadership.

Before and during the early period of neuroClues, he worked at IBA, where he was R&D proton therapy project manager from September 2017, program manager from August 2018 and head of project management from May 2020 until February 2021. He had earlier spent two periods at Group-IPS, first as a project engineer from February 2011 to April 2013 and then, from February 2015 to September 2017, as senior engineering project manager and food and beverage industry manager. In between he was an assistant manager at Bundaberg Sugar. He began his career as a consultant in biotechnology at Alcimed in 2009, followed by a year as a scientific assistant at the Scientific Institute of Public Health.

He holds a master in bioengineering, agronomical studies, from the Université libre de Bruxelles, awarded magna cum laude, and a bachelor in bioengineering, environmental studies, from the Université catholique de Louvain. He also studied at Victoria University of Wellington.

Career history

1. FounderneuroClues

Media & appearances

• Brain Innovation DaysYouTube
  Antoine Pouppez, CEO & co-founder of neuroClues - Brain Innovation DaysAntoine Pouppez describes neuroClues' mission to become a "brain stethoscope" by measuring eye movements to assess brain health and evaluate how the brain is functioning for clinical purposes. He explains that participating in Brain Innovation Days is important because the brain tech ecosystem is still in its early stages of development, and supporting its growth and enabling interaction with other players in the field is crucial for the industry's structuring.
• Peer EffectYouTube
  Why This MedTech Founder Refuses to Outsource, Even at £25M Raised - Antoine PouppezAntoine Pouppez discusses his origin story as an entrepreneur who partnered with neuroscientists to build Neuroclues, a medtech venture that has raised 25 million euros and grown to over 40 team members across Belgium and France. He shares key lessons from scaling the company, emphasizing the importance of being optimistic, resilient, and naively determined to overcome obstacles, and advocates for prioritization through an "urgent and important" framework to focus on core value delivery rather than attempting everything at once.
• BFM BusinessYouTube
  French Tech: neuroClues, a "brain stethoscope"Antoine Pouppez discusses neuroClues, a device that measures eye movements at over 400 images per second to help neurologists better understand central nervous system function and diagnose neurological conditions. He explains that the technology is currently deployed in about thirty establishments and is being used to differentiate types of Parkinson's disease and improve diagnostic accuracy, with plans to expand to other indications like concussions, dementia, and multiple sclerosis, and to reach approximately 10 million patients across Europe and the United States within 7 to 10 years.